Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark

XenoPort Reports Positive Results From A Phase 2 Trial Of Arbaclofen Placarbil In Spinal Cord Injury Patients With Spasticity
XenoPort, Inc. (Nasdaq:XNPT) announced positive preliminary results from a Phase 2 clinical trial of arbaclofen placarbil (AP), also known as XP19986, for the treatment of patients with spasticity due to spinal cord injury (SCI). Doses of 20 and 30 mg of AP, given twice daily (BID), demonstrated statistically significant improvements compared to placebo for the primary endpoint of the study. AP was well tolerated during the trial.
generic viagra online
Triglycerides Implicated In Diabetes Nerve Loss
A common blood test for triglycerides - a well-known cardiovascular disease risk factor - may also for the first time allow doctors to predict which patients with diabetes are more likely to develop the serious, common complication of neuropathy.
News of the day
Voice Box Can Be Preserved, Even With The Largest Cancers
Some patients with large tumors on their larynx can preserve their speech by opting for chemotherapy and radiation over surgery to remove the voice box.
Public Health

Mixed Neurodegenerative Disorders Are Emerging From The Shadows

Many cases of age-related neurodegenerative disease fall into the gray zone between big, defined diseases - Alzheimer"s or Parkinson"s, for example. Their diagnostic accuracy is low, researchers agree. That"s a problem, because mixed disease is not only common, but also quite different in its course from pathologically "pure" disease. (Mixed disease is often worse.) But there"s also excitement and opportunity. The large overlap between established neurodegenerative diseases is ripe for scientific exploration, and recent advances at the genetic, clinico-pathologic, and molecular levels have turned it into a dynamic area of research. In particular, diseases such as Dementia with Lewy bodies and frontotemporal dementias are drawing intense interest as biomarker development branches out beyond Amyloid beta and tau, holding out a future where molecular-based diagnoses can define the pathogenic proteins that together drive a given person"s individual disease. The Alzheimer Research Forum (www.alzforum.org), founded in 1996, is the web"s most dynamic scientific community dedicated to understanding Alzheimer disease and related disorders. Access to the web site is free to all. The Forum"s editorial priorities are as diverse as the needs of the research community. The web site reports on the latest scientific findings, from basic research to clinical trials; creates and maintains public databases of essential research data and reagents; and produces discussion forums to promote debate, speed the dissemination of new ideas, and break down barriers across the numerous disciplines that can contribute to the global effort to cure Alzheimer"s disease. The ARF team of professional science writers and editors, information technology experts, web developers and producers all work closely with its distinguished and diverse Advisory Board to ensure a high quality of information and services. The Alzheimer Research Forum is an independent nonprofit organization supported by grants and individual donations. The web site does not endorse any specific product or scientific approach. Alzheimer Research Forum Foundation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009